Influence of IGF-I serum concentration on muscular regeneration capacity in patients with sarcopenia

Stefanie Jarmusch1, Lisa Baber1, Martin Bidlingmaier2, Uta Ferrari1, Fabian Hofmeister1, Stefan Hintze3, Stefan Mehaffey4, Peter Meinke3, Carl Neuerburg4, Benedikt Schoser3, Fabiana Tanganelli1 and Michael Drey1*

Abstract

Background: Previous research has described a neuroprotective effect of IGF-I, supporting neuronal survival, axon growth and proliferation of muscle cells. Therefore, the association between IGF-I concentration, muscle histology and electrophysiological markers in a cohort of patients with sarcopenia dares investigation.

Methods: Measurement of serum concentrations of IGF-I and binding partners, electromyographic measurements with the MUNIX (Motor Unit Number Index) method and muscle biopsies were performed in 31 patients with acute hip fracture older age 60 years. Molecular markers for denervation (neural cell adhesion molecule NCAM) and proliferation markers (Ki67) were assessed by immunofluorescence staining of muscle biopsy tissue. Skeletal muscle mass by bioelectrical impedance analysis and hand-grip strength were measured to assess sarcopenia status according to EWGSOP2 criteria.

Results: Thirty-one patients (20 women) with a mean age of 80.6 ± 7.4 years were included. Concentrations of IGF-I and its binding partners were significantly associated with sarcopenia (ß = −0.360; p = 0.047) and MUNIX (ß = 0.512; p = 0.005). Further, expression of NCAM (ß = 0.380; p = 0.039) and Ki67 (ß = 0.424; p = 0.022) showed significant associations to IGF-I concentrations.

Conclusions: The findings suggest a pathogenetic role of IGF-I in sarcopenia based on muscle denervation.

Keywords: Insulin-like growth factor 1, MUNIX, Muscle atrophy, Denervation

Background

Sarcopenia, the progressive and age-associated loss of skeletal muscle mass and function [1] is a major reason for dependency and mortality in ageing societies. It is affecting around 6 to 22% of those older than 65 years [2]. Consequential falls, fractures, immobility and mortality add up to at least US $12–26 billion in health care costs annually in the United States of America alone [3] and thus place an enormous economic burden on the healthcare systems. As populations globally continue to age, wide-ranging research has been conducted in this field, yet the pathogenesis of sarcopenia is still not fully understood. It is believed to be a multifactorial pathogenesis, including several different factors such as an imbalance in protein metabolism and catabolism [4], satellite cell dysfunction and following type II muscle fiber atrophy [5], but also physical inactivity [6]. Dysregulation or reduction of testosterone, estrogen, growth hormone (GH) and insulin-like growth factor 1 (IGF-I) [7], as well as neurodegenerative factors, such as the loss of motor neurons and denervation resulting in muscle atrophy play another crucial role [8]. Beyond
motoneuron degeneration or peripheral nerve affection, denervation of muscle fibers can result from direct damage, atrophy or disruption of the neuromuscular junction and leads to muscle atrophy and possible myofiber death [9]. Several different electrophysiological techniques to estimate motor unit numbers have identified an association between low motor unit numbers and sarcopenia [10–12]. Histological evaluation of muscle tissue usually includes measurement of expression of the usually used histological marker for denervated myofibers neural cell adhesion molecule (NCAM). It is unclear whether the reinnervation capacity is reduced in patients with sarcopenia and what specific role IGF-I plays in that regard. IGF-I is known to be an important anabolic hormone in muscle metabolism and an important modulator of muscle growth and regeneration. IGF-I is produced in the liver in response to GH, a hormone produced by the pituitary gland. This hormonal regulation is referred to as the GH/IGF-I axis. Circulating IGF-I is usually bound in a ternary complex consisting of the acid labile subunit (ALS) and an insulin-like growth factor binding protein (IGFBP), whereof six different IGFBPs (IGFBP-1 to IGFBP-6) are existing with different tissue expression patterns [13]. IGF-I production can also be detected in the skeletal muscle itself [14] as a response to GH, testosterone or muscle stretch [15]. It promotes hypertrophic effects in skeletal muscle via proliferation of satellite cells, stimulation of protein synthesis [15] and myoblast proliferation and differentiation [16]. The antigen Ki67 is a nuclear protein that is associated with cellular proliferation and a suitable molecule to study proliferation in muscle cells [17]. Transgenic mice overexpressing a local muscle isoform of IGF-I display massive muscle hypertrophy, supporting the anabolic effects of IGF-I [18]. GH secretion and subsequent IGF-I production is markedly reduced while aging [15] with consequently poor muscle strength and poor physical performance [19, 20]. Another important function of IGF-I is its growth promoting effect on the peripheral and central nervous system. As a growth factor, it has potent effects on neurons, including enhancing neuronal survival, neurite formation and outgrowth in motoneurons [21, 22]. In particular, IGF-I has a stimulating effect on axonal sprouting and damage repair [22, 23]. It therefore has been considered and tested as a potential therapeutic drug in neurodegenerative diseases like amyotrophic lateral sclerosis [24–26].

Since IGF-I is a key growth factor in muscle tissue and also in the peripheral and central nervous system by promoting neuronal survival, this study focuses on the association of IGF-I concentrations and number of motor units measured by MUNIX, and expression of NCAM and Ki67 in patients with sarcopenia.

Methods
Participants
In collaboration with the Department of General-, Trauma- and Reconstructive Surgery of the University Hospital Munich, we recruited 31 hip fracture patients undergoing surgery aged 60 years or above from November 2017 to March 2019. Exclusion criteria included age younger than 60 years, specific neuromuscular diseases (e.g. myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, polio, myositis), dementia, chronic inflammatory diseases (e.g. Crohn’s disease, ulcerative colitis, rheumatoid arthritis), systemic corticosteroid therapy, and cancer therapy in the last 5 years. The study protocol was approved by the Ethics Committee of LMU Munich (IRB-No. 328–15). All participants gave their written informed consent before surgery.

Sarcopenia assessment
Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria [27]. Bioelectrical impedance analysis (BIA) was done under standard conditions, with the patient in a supine position and surface electrodes placed on the wrist and ankle contralateral to the side of the fracture. Appendicular lean mass (aLM) was estimated using the equation developed by Sergi et al. [28]. The skeletal muscle index (SMI, [kg/m²]) was calculated by dividing aLM by squared body height. Thresholds for low muscle mass were defined as SMI below 7 kg/m² in men and 5.5 kg/m² in women. Handgrip strength was assessed with a Saehan DHD-1 Digital Hand Dynamometer, with the patient sitting upright and the arm held in a 90-degree flexion. Three consecutive measurements of both hands were taken and the maximum value was obtained. Thresholds for handgrip strength were 27 kg for men and 16 kg for women [27]. Patients were classified as being sarcopenic by low muscle mass and low handgrip strength. A z-score combining handgrip strength and muscle mass was calculated separately for men [z-score sarcopenia men = [(27 – handgrip strength)/SD (hand-grip strength)] + [(7.0 – SMI)/SD (SMI)] and women [z-score sarcopenia women = [(16 – handgrip strength)/SD (hand-grip strength)] + [(5.5 – SMI)/SD (SMI)]. The higher the Z-score, the more sarcopenic the patient. Measurements were carried out between two and 7 days after surgery (mean value: 4 days).

Muscle biopsies
Open biopsy of the vastus lateralis muscle was performed during surgery for hip fracture. The biopsy was directly cryo-conserved. Muscle tissue blocks were cut to 10 μm tissue sections on a cryostat (HM505E; Micron, Walldorf, Germany) at −26°C Celsius and mounted on...
glass slides (double frosted microscope slides; Fisher Scientific), air dried for 2 h and stored at −80° Celsius.

**Immunofluorescence staining for NCAM and Ki67**

Muscle sections were cautiously defrosted from −80° Celsius and allowed to air dry for 15 min at room temperature. For NCAM staining, the sections underwent several washing cycles with blocking solution (TBS, 0.1%, and Gelatin Fish, 0.9%) and were incubated with the primary antibody for NCAM overnight (polyclonal rabbit anti-NCAM (ab5032, 1:100; Millipore Sigma). After incubation and washing cycles with TBS 0.1%, the tissue sections were incubated with the second antibody (anti-rabbit Alexa Fluor plus 594, 1:500; Invitrogen) and afterwards covered with fluorescence mounting medium with DAPI (Vertor Laboratories, Inc. Burlingame, CA 94010). NCAM expression was detected by counting randomly selected 100 to 150 cells with a Zeiss Fluorescence microscope (Zeiss Axiocyt 200 M fluorescence microscope, Zeiss, Oberkochen, Germany).

Assessment of proliferation of the muscle cells was determined using an immunohistochemistry assay with the proliferation marker Ki67 on myoblast cell culture cells gained from muscle biopsy tissue. Cells were washed 3 times with 1x Tris-buffered Saline (TBS) and incubated in blocking solution, containing TBS/Tween (20%) and Fish Gelantine (1%) in a ratio of 10:1 followed by overnight incubation in the primary antibody solution, containing Ki67 (1:100 Donkey anti Rabbit IgG Alexa Fluor™ Plus 594, Invitrogen) dissolved in blocking solution. After 3 washing cycles, the cells incubated for 1 h in the secondary antibody solution (1:500 Donkey anti-Mouse IgG [H + L] Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 594), dissolved in blocking solution. Coverslips were then covered with 30μl Mounting Medium containing DAPI (Vectashield) and incubated in a darkened staining chamber. Immunofluorescence images were acquired using a microscope (Olympus fluoresview FV1000) and an oil immersion 20x objective and the Olympus Fluoview Software (version 4.2.a). The optical fields were selected randomly to count 100 to 150 cells with Image J (Version 2.0.0).

**MUNIX/MUSIX measurements**

The MUNIX technique is an electromyographic method for estimation of number and size of motor units (MUNIX = Motor unit number index, MUSIX = Motor unit size index) based on a mathematical model first described by Nandedkar [29]. Electrodes (15 mm × 20 mm; CareFusion, Middleton, Wisconsin, USA) were placed over the motor point of the hypothenar muscle (active electrode), on the distal hypothenar phalanx (reference electrode) and on the wrist (ground electrode) of the non-fractured patient side. An EMG device (NATUS, Pleasaton, CA, USA) was used. Briefly, the MUNIX procedure consists of 3 steps. The first step is the measurement of the compound muscle action potential (CMAP) by supramaximal stimulation of the ulnar nerve. Three consecutive supramaximal stimulations were performed to obtain the highest CMAP amplitude used for calculation of its amplitude, area and power. Secondly, the surface electromyographic interference patterns (SIPs) are measured. Patients were instructed to exert and maintain an isometric contraction of the hypothenar muscle at varying levels and repeated several times in order to obtain 18 different SIPs. CMAP and SIP were recorded using a bandpass filter setting of 3-3000 Hz. Area and power of the signals were calculated for calculation of MUNIX (MUNIX = A • (20mVms)^3). MUSIX is then calculated by dividing the CMAP amplitude by MUNIX: MUSIX = Amplitude (CMAP)/MUNIX [μV]. It should be noticed that MUNIX and MUSIX are no absolute values but equivalents of number and size of a motor unit. To prevent biases caused by artifacts in the SIP epochs, only those SIPs eligible for the following criteria, as proposed by Nandedkar [30], were accepted for analysis: (a) SIP area > 20mVms; (b) Ideal case motor unit count (ICMUC) < 100; (c) SIP area/CMAP area > 1. MUNIX values < 80 and MUSIX values > 100 μV were classified as low or pathological [30]. Further background information on the mathematical model can be found in earlier publications by Drey et al. [12] and in the Additional file 1.

**Laboratory measurements**

Blood samples for measurement of serum concentrations of IGF-I, IGFBP-3 and ALS as parameter for the somatotropic axis were obtained on the third postoperative day. After centrifugation, the serum was stored at −80° Celsius until analysis. Serum hormone concentrations (ng/ml) of IGF-I and IGFBP-3 were measured at the Endocrine Laboratory of the University Hospital Munich (KUM, Germany) using the IDS-iSYS automated chemiluminescent assay system (Immunodiagnostics System Ltd., Boldon, England, UK). Validation data for all assays and reference intervals have been published elsewhere [31, 32]. The assays are calibrated against the latest recombinant standards (98/574 for GH and 02/254 for IGF-I). Serum ALS concentrations were measured in duplicate by a sandwich-type immunofluorometric assay using monoclonal antibodies directed against specific N- and C-terminal oligopeptides [33]. A serum pool of healthy male volunteers was used for calibration and assigned 1000 U/L. The assay range is 100–1500 U/L, and intra- and inter-assay CVs are below 9%.
Statistical analysis
Statistical analyses were performed using IBM software SPSS v26.0 (IBM-SPSS Inc., Chicago, II, USA). Participants’ characteristics were expressed as mean values and their standard deviation (Table 1). Group differences were calculated by Student’s t-test. Scatter plots and Pearson’s correlation coefficients were shown to visualize correlations between IGF-I and Z-score sarcopenia, MUNIX, MUSIX, NCAM and Ki67 (Figs. 1, 2 and 3). As our study cohort comprise 20 women and only 11 men, multiple linear regression analysis was used to adjust the relations between IGF-I and MUNIX, MUSIX, NCAM and Ki67 for gender (Figs. 2 and 3). In all these models, IGF-I is the independent variable, whereas MUNIX, MUSIX, NCAM and Ki67 are dependent variables. The adjustment is not necessary for the relation between IGF-I and Z-score sarcopenia, as gender is reflected in the Z-score (Fig. 1). Statistical significance was set at \( p < 0.05 \) for all analyses.

Results
The participants’ characteristics are shown in Table 1. A total of 31 patients (20 women) with a mean age of 80.6 ± 7.4 years were recruited. Two participants did not tolerate the MUNIX procedure. Due to insufficient antibody binding, only 29 muscle biopsies could be evaluated for Ki67 expression and 30 biopsies for NCAM expression. The cohort was divided by gender (20 women, 11 men). The groups differed significantly in maximal handgrip strength (\( p = 0.030 \)) and the severity of sarcopenia represented by z-score sarcopenia (\( p = 0.040 \)), showing that men were more affected by sarcopenia than women. Furthermore, men had significant lower MUNIX (\( p = 0.032 \)) and higher MUSIX values (\( p = 0.030 \)) than women in this cohort. Serum hormone concentrations for IGFBP-3 (\( p = 0.033 \)) and ALS (\( p = 0.016 \)) in male participants were significantly reduced compared to female participants. IGF-I levels did not differ significantly between gender (\( p = 0.296 \)). No significant difference in the expression pattern of the histological proliferation marker Ki67 and denervation marker NCAM between male and female participants were found.

Sarcopenia severity correlates with IGF-I concentrations
Figure 1 shows the relation between the degree of sarcopenia (represented by the z-score sarcopenia) and IGF-I serum concentrations. Pearson’s correlation coefficient was −0.360 (\( p = 0.047 \)), representing that patients with reduced serum concentrations of IGF-I are significantly more affected by sarcopenia. This effect does not remain after adjustment for sex (\( b = -0.299; p = 0.089 \)).

MUNIX and MUSIX measurements
Two participants did not tolerate the MUNIX procedure. Thirteen participants presented with pathological MUNIX values below the threshold of 80 (6 women, 7 men) and 7 participants (3 women, 4 men) with pathological MUSIX values above the threshold of 100 μV. Two MUSIX results had to be excluded from analysis due to unreliable measurement.

Figure 2 illustrates the relation between IGF-I concentrations and MUNIX (Fig. 2a) and MUSIX values (Fig. 2b). Pearson’s correlation coefficient between IGF-I concentrations and MUNIX was \( b_1 = 0.512 \) (\( p = 0.005 \)) and \( b_1 = -0.551 \) (\( p = 0.003 \)) between IGF-I and MUSIX. These significant correlations remain after

Table 1 Patients characteristics stratified for gender

|                     | Total sample n = 31 | Female n = 20 | Male n = 11 | p-Value |
|---------------------|---------------------|---------------|-------------|---------|
| Age [years]         | 80.6 (7.4)          | 79.6 (8.4)    | 82.5 (5.2)  | 0.306   |
| Handgrip strength [kg]| 23.2 (8.9)      | 20.6 (6.9)    | 27.8 (10.6) | 0.030   |
| SMI [kg/m²]         | 6.9 (1.2)           | 6.7 (1.2)     | 7.3 (1.3)   | 0.163   |
| z-score sarcopenia  | 1.2 (1.8)           | 1.7 (1.8)     | 0.3 (1.9)   | 0.040   |
| IGF-I [ng/ml]       | 64.1 (25.6)         | 67.8 (25.0)   | 57.5 (26.7) | 0.296   |
| IGFBP-3 [ng/ml]     | 1577 (544)          | 1729 (542)    | 1300 (446)  | 0.033   |
| ALS [mU/ml]         | 259 (131)           | 301 (126)     | 182 (104)   | 0.013   |
| MUNIX               | 95 (43)             | 107 (43)      | 72 (33)     | 0.032   |
| MUSIX [μV]          | 87 (35)             | 77 (18)       | 106 (51)    | 0.030   |
| Ki67+ myocytes [%]  | 48.6 (17.9)         | 50.0 (18.2)   | 46.3 (18.0) | 0.600   |
| NCAM+ fibers [%]    | 1.1 (1.6)           | 1.1 (1.8)     | 1.0 (1.2)   | 0.797   |

Mean (SD) unless stated otherwise. Two patients did not tolerate the MUNIX procedure. Two missing measurements for Ki67 staining and 1 missing for NCAM expression due to insufficient antibody binding. SMI Skeletal muscle index, IGF-I Insulin-like growth factor 1, IGFBP-3 Insulin-like growth factor binding protein 3, ALS Acid labile subunit, MUNIX Motor unit number index, MUSIX Motor unit size index, NCAM neural cell adhesion molecule. p-values between groups were calculated using two sample-t-test. p-Values <.05 are bold.
adjustment for sex (MUNIX: $\beta_2 = 0.436$, $p = 0.014$; MUSIX: $\beta_2 = -0.545$, $p = 0.008$).

**Ki67 and NCAM expression in dependence of IGF-I**

Due to insufficient antibody binding, only the material of 29 muscle biopsies could be evaluated for Ki67 expression and material of 30 biopsies for NCAM expression.

Figure 3 shows the relation between IGF-I concentrations and Ki67+ myocytes derived from muscle biopsy tissue (Fig. 3a), the histological marker for proliferation, and NCAM (Fig. 3b), a molecule that marks denervation/reinnervation processes in muscle tissue. Between IGF-I concentrations and the expression of Ki67 in myocytes a linear correlation was observed ($\beta_1 = 0.424; p = 0.022$), as well as between IGF-I concentrations and the percentage of NCAM expressing muscle fibers ($\beta_1 = 0.380; p = 0.039$). These linear correlations remained after adjustment for sex (Ki67: $\beta_2 = 0.422$, $p = 0.028$; NCAM: $\beta_2 = 0.387$, $p = 0.043$).

**Discussion**

The main finding in our study is the significant association between IGF-I serum concentration, low numbers of motor units, NCAM and Ki67 expression. This finding emphasizes the important role of IGF-I on cell proliferation and reinnervation processes in aged muscle.

Our first finding in this study is the association of the severity of sarcopenia (z-score sarcopenia) in geriatric patients with reduced serum concentrations of IGF-I (Fig. 1). Since the pathogenesis of sarcopenia is believed to be multifactorial, endocrinological changes in aging play a key role in the multifactorial pathogenesis of sarcopenia. Research in mice and humans over the past decade has clarified the anabolic role of IGF-I as a growth factor in muscle metabolism [34] by promoting myoblast proliferation and differentiation and stimulation of satellite cell proliferation and muscle protein synthesis [35]. It had been concluded that reduced IGF-I concentrations in aging contribute to sarcopenia, i.e. the InCHIANTI study on 730 subjects showed that lower IGF-I concentrations were associated with the higher risk to develop sarcopenia [36]. We also demonstrate that correlation (Fig. 1) in our small sample of geriatric hip fracture patients, that shows a significant reduced IGF-I hormonal axis in total in our cohort independent from sex (Table 1) thus providing additional evidence for the assumption of an association between low levels of IGF-I and sarcopenia.

The second main finding in our cohort is the association of a reduced number of motor units in geriatric patients with reduced serum concentrations of IGF-I (Fig. 2a). Approaches to explain the age-related loss of muscle mass include the assumptions that either loss of muscle fibers due to denervation, degeneration of the neuromuscular junction, loss of motor units itself or all of those together are causative factors in sarcopenia [37]. Previous research on neuronal changes in aging muscle revealed a loss of motor units with age [38], whereas the remaining motor units increase in size as a compensation mechanism [39]. Drey et al. were the first to demonstrate motor unit loss in patients with sarcopenia [8].
They also used the MUNIX technique by Nandedkar et al. [29] to quantify the number of motor units in community-dwelling older adults. This electromyographic method using the hypothenar muscle as an 'indicator muscle’ was initially developed for evaluation of disease progression in patients with amyotrophic lateral sclerosis [29], in which a progressive loss of first and second motor neurons occurs. Although we had examined older adults with acute hip fracture, the MUNIX technique is a valid method and previously has been shown to be applicable in patients with sarcopenia [12]. In our cohort, half of the included patients (51.6%) presented with low MUNIX values, meaning values below the threshold of 80, a cut-off suggested by Nandedkar et al. [30]. Our results show a significant association between low MUNIX values and a higher degree of sarcopenia, represented by a z-score sarcopenia (β = −0.411, p = 0.027, data not shown). We used this z-transformation including handgrip strength and muscle mass values with cut-offs according to the EWGSOP II criteria [27] to display the degree of sarcopenia in each patient and to classify the sarcopenia status even if patients were not entirely fulfilling the sarcopenia criteria. Our results support the previous findings of motor unit

Fig. 2 Relation of IGF-I serum concentrations and MUNIX (A) and MUSIX values (B) stratified by sex. Legend: Two participants did not tolerate the MUNIX procedure and two MUSIX results had to be excluded from analysis due to unreliable measurement. β1 = unadjusted regression coefficient, β2 = regression coefficient adjusted for sex, IGF-I = insulin-like growth factor 1, MUNIX = Motor unit number index, MUSIX = Motor unit size index.
loss occurring in a geriatric population and are thus a conceivable contributing factor in sarcopenia development. The participants with reduced MUNIX values also show significant higher MUSIX values, representing the size of motor units. Since these participants were more affected by sarcopenia, this result supports our hypothesis of compensatory mechanisms in motoneurons such as neuronal sprouting. Since Drey et al. showed that the odds ratio for being sarcopenic with pathological MUNIX and MUSIX values is three times higher compared to a healthy control group [8], our results provide further evidence for MUNIX as a potential biomarker for sarcopenia caused by motoneuron loss and for its prospective clinical use in geriatrics. Nevertheless, the correlations could result either due to the relatively small sample size (n = 31) or it could be attributed to the remaining muscle fibers and their remaining motoneurons increasing in size [40].

Our data further demonstrate a possible link between endocrinological and neuronal changes in sarcopenia, as
we found a significant reduced IGF-I hormonal axis in total in our cohort independent from sex (Table 1) as well as significant correlations of reduced IGF-I concentrations and low MUNIX values and MUSIX values in general (Fig. 2a and b). The neurotrophic role of IGF-I in the nervous system has been described before [41]. In particular, the hormone stimulates axonal sprouting and damage repair of motoneurons [22], thus contributing to reinnervation and regenerative processes, a decreased repair mechanism in age. Musaro et al. designed a transgenic mouse model expressing a full-length precursor of a localized IGF-I isoform, mIGF-I, which expression is normally induced after muscle damage. This muscle specific isoform maintains muscle hypertrophy and regenerative potential in aged muscle [18], supports recruitment of satellite cells in damaged muscle [42] and improves muscle mass and strength all by mediating associated pathways in muscle growth [34]. IGF-I supplementation therefore might be considered as a therapeutic drug in neuronal muscle wasting and sarcopenia. Neuronal sprouting after muscle fiber denervation seems to be limited in aging muscle tissue. This could be due to a loss of regeneration capacity or due to loss of possibility to signal the denervation status to surrounding muscle fibers. IGF-I might be one of the local stimulating hormone to support muscle and motor unit growth after denervation, but it is not yet known whether IGF-I also supports signaling. The significant correlation of higher MUSIX values with lower IGF-I concentrations (Fig. 2b) suggests that IGF-I either might not be involved in that local signaling or its concentration is too low.

To study regenerative potential of aged muscle, we measured the expression of Ki67 and NCAM in the muscle biopsy specimens. Ki67 protein is a widely used marker for cell proliferation in human tumor cells, especially in breast cancer. It is also commonly used as a marker in immunofluorescence staining techniques in detecting proliferating cells in any tissue including muscle cells [17, 43]. The neural cell adhesion molecule (NCAM) is a molecule expressed by muscle cells involved in muscle-neuron and muscle-muscle cell interactions. Its expression is regulated by the state of innervation of a muscle cell [44]. Accumulation of NCAM in a denervated and paralyzed skeletal muscle was first shown by Covault et al. [45]. Levels of NCAM expression since then display denervated muscle fibers in neurogenic disorders and aged muscle, even though Hendrickse et al. recently pointed out that NCAM may not be as useful as expected to detect denervation. His group studied the expression of NCAM upon time course of denervation duration and could not find a difference in NCAM levels in long term denervation compared to the control group after nerve injury [46].

However, NCAM stays a marker for early muscle fiber denervation. Our analysis in the muscle biopsy specimens reveals a significant correlation of reduced IGF-I concentrations in older adults and low Ki67 expression, thus a reduced amount of muscle fibers in a proliferating state (Fig. 3a). We further show, that if denervation occurs in aged muscle, the level of reinnervation (represeted by NCAM expression in muscle tissue) seems to be correlating with IGF-I concentrations (Fig. 3b), indicating a connection of endocrine and neurological factors in the pathogenesis of sarcopenia.

It has yet not been described if IGF-I itself is able to directly upregulate the Ki67 protein on a molecular level, but it is known that IGF-I activates satellite cell growth and proliferation, therefore promoting muscle growth via the stimulation of the Akt/mTOR pathway [47]. Our findings support this anabolic role and justify the use of Ki67 as proliferation marker in aged muscle tissue. Further, our results demonstrate evidence for the hypothesis of failed denervation and reinnervation processes in sarcopenia, because the latter being dependent on sufficient IGF-I concentrations. The process of neuronal sprouting of mature axons as a rescue mechanism after nerve injury or denervation takes place in the entire nervous system and during all periods of life [48]. Kanda et al. reported restorage of the motor function in the medial gastrocnemius muscle of aged rates after nerve crush injury, suggesting that aged motoneurons preserve their capacity for axonal reinnervation [49]. In aging, motor unit loss occurs and results in denervated muscle fibers, which compensate the loss with reinnervation by axonal sprouting, a process called motor unit remodeling [50]. In turn, this leads to an increase in the size of motor units of the remaining motor units, as shown by the increased MUSIX values in our cohort. We found an association of high NCAM expression with higher IGF-I concentrations, stating that IGF-I might support the expression of NCAM. Gillon et al. [51] recently concluded that NCAM might be the decisive signal molecule for aged denervated muscle fibers to signal their denervation status to surrounding motoneurons. The ability to do so seems to be reduced in aged muscle, therefore missing the ability to reattract a neuronal input for reinnervation. In our cohort the NCAM levels significantly correlated to the IGF-I serum concentrations, showing a possible supportive role of IGF-I in reinnervation processes by supporting the potential to express in NCAM in aged muscle fibers after denervation in order to get reinnervated and prevent disuse atrophy. As we could only find NACM expression in muscle tissue in 12 of 31 muscle biopsies, this could be either due to the fact that these geriatric patients were just too ill to signal their denervation status and therefore lost the potential for reinnervation processes, or this failed reinnervation is due
to a lack of systemic IGF-I. Nevertheless, this does not fully explain inverse correlation of MUSIX values, that represent the size of motor units, with IGF-I concentrations. Either denervation was not the main atrophy trigger in those patients or reinnervation failed in half of the cohort due insufficient IGF-I concentrations. Since an neuroprotective influence of IGF-I has been described [41], systemic administration of IGF-I has already been used in therapeutic trials in neurodegenerative and muscle atrophy associated diseases such as amyotrophic lateral sclerosis patients [24–26] and recently in older adults [52, 53]. Unfortunately, all studies in amyotrophic lateral sclerosis patients did not show any significant improvement in disease progression or muscle strength. One critical problem is the effective delivery of the neurotrophins to their target cells [54]. In turn, Butterfield et al. demonstrated increased muscle protein synthesis in response to one-month IGF-I supplementation in 14 older female adults [52], whereas Friedlander et al. could not find any changes in body composition, bone mineral density or handgrip strength after one-year IGF-I replacement [53]. These previous trials and results, combined with our findings, lead us to the assumption that sufficient IGF-I concentrations play a crucial role in muscle loss on the molecular level, in both endocrinological and neurological sarcopenia by establishing an anabolic environment. IGF-I supplementation should still be considered as a pharmacological treatment option in a subgroup of neurogenic affected patients with sarcopenia as it might promote the supportive endocrinological environment needed for sufficient muscle regeneration after denervation. Further studies on the regenerative capacity of aged muscle associated to IGF-I in sarcopenia would help to elucidate this potential anabolic treatment.

The main strength of our study certainly is the use of valuable muscle biopsy material of a geriatric patient cohort and the corresponding histological and electrophysiological examinations, including a comprehensive investigation of the GH/IGF-I axis. However, some limitations should be noted. Firstly, the study is conducted in a cross-sectional study design which cannot prove causality. The correlations shown in the figures are just weak to moderate which is quite common in clinical samples. Secondly, we cannot entirely rule out misevaluation of sarcopenia status, as sarcopenia assessment was conducted right after surgery. Thirdly, given the relatively small study population, we cannot give general statements for a general population. Strictly speaking our results are only valid for hip fracture patients with sarcopenia and are therefore not generalizable for the whole group of patients with sarcopenia.

Conclusion
To our knowledge, this is the first study to demonstrate a correlation of reduced IGF-I serum concentrations and markers of denervation in sarcopenia. Considering the small study population and the cross-sectional study design, a longitudinal observation of participants would be helpful to further elucidate these associations. Performance could be increased by a structured, continuous, and longitudinal bio-banking of muscle biopsies, especially in an orthogeriatrics setting. Our data open a new window for a discussion for IGF-I as a pharmacological agent in prevention and treatment in patients with sarcopenia, as it might be the vital hormone for establishing a sufficient environment for muscle regeneration in age by supporting neuronal reinnervation of denervated muscle fibers.

Abbreviations
alM: Appendicular lean mass; ALS: Acid labile subunit; BIA: Bioelectrical impedance analysis; CMAP: Compound muscle action potential; EGWSCP: European Working Group on Sarcopenia in Older People; EMG: Electromyography; GH: Growth Hormone; ICMMUC: Ideal case motor unit count; IGF-I: Insulin-like growth factor 1; IGFBP-3: Insulin-like growth factor binding protein 3; MUNIX: Motor unit number index; MUSIX: Motor unit size index; NCAM: Neural cell adhesion molecule; SD: Standard deviation; SIP: Surface electromyographic interference pattern; SMI: Skeletal muscle mass index; TBS: Tris-buffered saline

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12891-021-04699-3.

Additional file 1.

Acknowledgments
We are grateful to all participants of the study. We thank the Friedrich-Baur-Institute (University Hospital of LMU Munich, Germany) and their technical team members for sharing their laboratories for the entire duration of the project as well as for their excellent assistance. Furthermore, we thank the Department of General-, Trauma- and Reconstructive Surgery of the KUM (University Hospital of LMU Munich, Germany) for performing the muscle biopsies and the whole team of the Endocrinological Laboratory of KUM (Department of Medicine IV, University Hospital of LMU Munich, Germany) for the laboratory measurements.

Authors’ contributions
Conceptualization, Methodology, Funding acquisition & Resources: MD; Measurements: SJ, FH, LB, FT, MB; Muscle biopsy sampling: SM, CN; Formal analysis: SJ; Writing - original draft preparation: SJ; Writing - review and editing: MD, BS; Supervision and interpretation of data: MD, BS, MB, UF, PM, SH. All authors have read and approved the final manuscript.

Funding
This work was supported by the project Keep Control of the European Union, funded under the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (Nr. 721577). The funders had no role in the design and conduct of the study, data collection and analysis, interpretation of data, or preparation of the manuscript. Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
All data generated or analysed during this study are included in this published article.
Declarations

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of LMU Munich (IRB-No. 328–15). All participants gave their written informed consent before surgery.

Consent for publication
Not applicable.

Competing interests
The authors declare no conflicts of interest or competing interests.

Author details
1Department of Medicine IV, Geriatrics, University Hospital of LMU Munich, Munich, Germany. 2Department of Medicine IV, Endocrinological Laboratory, University Hospital of LMU Munich, Munich, Germany. 3Friedrich-Baur-Institute, Department of Neurology, University Hospital of LMU Munich, Munich, Germany. 4Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital of LMU Munich, Munich, Germany.

Received: 9 February 2021 Accepted: 10 September 2021
Published online: 20 September 2021

References

1. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393:2636–46.
2. Dent E, Morley JE, Cruz-Jentoft AJ, Aral H, Kritz-Silverstein SE, Guralnik J, et al. International clinical practice guidelines for sarcopenia (ICF59): screening, diagnosis and management. J Nutr Health Aging. 2018;22:148–61.
3. Janisen I, Shepard DS, Katsmanyzk PT, Roubenoff R. The Healthcare Costs of Sarcopenia in the United States. J Am Geriatr Soc. 2004;52:862–5.
4. Breier L, Phillips SM. Skeletal muscle protein metabolism in the elderly: interventions to counteract the “anabolic resistance” of ageing. Nutr Metab. 2011;8:1.
5. Tanganelli F, Meinke P, Hofmeister F, Jarmusch S, Baber L. Type-2 muscle fiber atrophy is associated with sarcopenia in elderly men with hip fracture. Exp Gerontol. 2020;144:111171.
6. Szulc P, Duboeuf F, Marchad F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr. 2004;80:505–13.
7. Bian A, Ma Y, Zhou X, Guo Y, Wang W, Zhang Y, et al. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet Disord. 2020;21:214. https://doi.org/10.1186/s12891-020-02326-y.
8. Drey M, Krieger B, Sieber CC, Bauer JM, Hettwer S, Bertsch T, et al. Motoneuron loss is associated with sarcopenia. J Am Med Dir Assoc. 2014;15:535–9.
9. Grounds MD. Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology. 2002;3:19–24.
10. Piasecki M, Ireland A, Piasecki J, Stashuk DW, Bolon DD, Oppenheim RW, Grebow PE, et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol. 1993;124:73–88.
11. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-I in Amyotrophic Lateral Sclerosis. Neurology. 1998;51:583–6.
12. Lu EC, Felice JK, Testost BF, Gavel MJ, Gelinas DF, Kozat R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo-controlled study. Neurology. 1997;49:1621–30.
13. Sorenson EJ, Windbank AJ, Mandrekar JN, Bammard WR, Appel SH, Arnon C, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770–5.
14. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48:1616–31. https://doi.org/10.1093/ageing/afy169.
15. Sergi G, De Rui M, Veronese N, Belfracta F, Berton L, Carraro S, et al. Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. Clin Nutr. 2015;34:667–73.
16. Nandedkar SD, Nandedkar DS, Barkhaus PE, Ståberg EV. Motor unit number index (MUNIX): a subgroup of geriatric patients. J Clin Endocrinol Metab. 2020. https://doi.org/10.1210/clinem/dgaa972.
17. Alsharidah M, Lazarus NR, George TE, Agley CC, Velloso CP, Harridge SDR. Primary human muscle precursor cells obtained from young and old donors produce similar proliferative, differentiation and senescent profiles in culture. Aging Cell. 2013;12:333–44. https://doi.org/10.1111/acel.12051.
18. Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinari M, et al. Localized IGF-1 transgene expression sustains hyper trophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195–200.
19. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafé M, et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab. 2003;284:E481–7.
20. Tasci DI, Glazer GW, Pu SF. Role of insulin-like growth factors in peripheral nerve regeneration. Pharmacol Ther. 1994;62:125–44.
21. Vergani L, Di Giulio AM, Losa M, Rossini G, Muller EE, Geroni A. Systemic administration of insulin-like growth factor decreases motor neuron cell death and promotes muscle reinnervation. J Neurosci Res. 1998;54:940–7.
22. Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, et al. Insulin-like growth factor-I potential for treatment of motor neuronal disorders. Exp Neurol. 1993;124/73–88.
23. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al. A placebo-controlled trial of insulin-like growth factor-I in Amyotrophic Lateral Sclerosis. Neurology. 1998;51:583–6.
24. Lu EC, Felice JK, Fjestad BW, Gavel MJ, Gelinas DF, Kozat R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo-controlled study. Neurology. 1997;49:1621–30.
25. Sorenson EJ, Windbank AJ, Mandrekar JN, Bammard WR, Appel SH, Arnon C, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008;71:1770–5.
26. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48:1616–31. https://doi.org/10.1093/ageing/afy169.
27. Sergi G, De Rui M, Veronese N, Belfracta F, Berton L, Carraro S, et al. Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. Clin Nutr. 2015;34:667–73.
28. Nandedkar SD, Nandedkar DS, Barkhaus PE, Ståberg EV. Motor unit number index (MUNIX): a subgroup of geriatric patients. J Clin Endocrinol Metab. 2020. https://doi.org/10.1210/clinem/dgaa972.
29. Nandedkar SD, Nancedkar DS, Barkhaus PE, Ståberg EV. Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease. Muscle Nerve. 2010;42:789–807.
30. Bidlingmaier M, Friedrich N, Emery RT, Spranger J, Wolthers OD, Roswall J, et al. Reference intervals for insulin-like growth factor-1 (IGF-1) from birth to senescence: results from a multicenter study using a new automated Chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99:1712–21.
31. Friedrich N, Wolthers OD, Arafat AM, Emery RT, Spranger J, Wolthers OD, et al. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (igfbp-3) and the igf-i to igfbp-3 ratio measured by new automated chemiluminescence assays. J Clin Endocrinol Metab. 2014;99:1675–86.
32. Stadler S, Wu Z, Dresdendorfer RA, Morrison KM, Khare A, Lee PD, et al. Monoclonal anti-ace-fabile subunit oligopeptide antibodies and their use in a two-site immunoassays for ALS measurement in humans. J Immunol Methods. 2001;252:73–82.
33. Ascenz F, Barberi L, Dobrowolny G, Villa Nova Bacarau A, Nicolletti C, Rizzuto E, et al. Effects of IGF-I isoforms on muscle growth and sarcopenia. Aging Cell. 2019;18:1–11.
34. Vitale G, Cesi M, Mari D. Aging of the endocrine system and its potential impact on sarcopenia. Eur J Intern Med. 2016;35:10–5. https://doi.org/10.1016/j.ejim.2016.07.017.
35. Volpato S, Bianchi L, Cherubini A, Landi F, Maggio M, Savino E, et al. Prevalence and clinical correlates of sarcopenia in community-dwelling older people: application of the EWGSOP definition and diagnostic algorithm. J Gerontol A Biol Sci Med Sci. 2014;69:438–46.
36. Delbono O. Neural control of aging skeletal muscle. Aging Cell. 2003;2:21–9.
37. McNeil CJ, Doherty TJ, Stashuk DW, Rice CL. Motor unit number estimates in the tibialis anterior muscle of young, old, and very old men. Muscle Nerve. 2005;31:461–7.
39. Doherty TJ, Vandervoort AA, Brown WF. Effects of ageing on the motor unit: a brief review. Can J Appl Physiol. 1993;18:331–58.
40. Clark DJ, Fielding RA. Neuromuscular contributions to age-related weakness. J Gerontol A Biol Sci Med Sci. 2012;67:741–7.
41. Musarò A, Dobrowolny G, Rosenthal N. The neuroprotective effects of a locally acting IGF-1 isoform. Exp Gerontol. 2007;42:76–80.
42. Musarò A, Giacinti C, Borrellino G, Dobrowolny G, Pelosi L, Caims L, et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A. 2004;101:1206–10.
43. Zhang C, Cheng N, Qiao B, Zhang F, Wu J, Liu C, et al. Age-related decline of interferon-gamma responses in macrophage impairs satellite cell proliferation and regeneration. J Cachexia Sarcopenia Muscle. 2020;11:1291–305. https://doi.org/10.1002/jcsm.12584.
44. Andersson AM, Olsten M, Zhernosekov D, Gaardsvoll H, Krog L, Linnemann D, et al. Age-related changes in expression of the neural cell adhesion molecule in skeletal muscle: a comparative study of newborn, adult and aged rats. Biochem J. 1993;290:641–8.
45. Covault J, Sanes JR. Neural cell adhesion molecule (N-CAM) accumulates in denervated and paralyzed skeletal muscles. Proc Natl Acad Sci U S A. 1985;82:4544–8.
46. Hendrickse P, Galinska M, Hodson-Tole E, Degens H. An evaluation of common markers of muscle denervation in denervated young-adult and old rat gastrocnemius muscle. Exp Gerontol. 2018;106:159–64.
47. Pallafacchina G, Blaauw B, Schiaffino S. Role of satellite cells in muscle growth and maintenance of muscle mass. Nutr Metabol Cardiovasc Dis. 2013;23:512–8.
48. Brown MC, Holland RL, Hopkins WG. Motor Nerve Sprouting. Annu Rev Neurosci. 1981;4:17–42.
49. Kanda K, Hashizume K. Recovery of motor-unit function after peripheral nerve injury in aged rats. Neurobiol Aging. 1991;12:271–6.
50. Vandervoort AA. Aging of the human neuromuscular system. Muscle Nerve. 2002;25:17–25.
51. Gillon A, Sheard P. Elderly mouse skeletal muscle fibres have a diminished capacity to upregulate NCAM production in response to denervation. Biogerontology. 2015;16:811–23.
52. Butterfield GE, Thompson J, Rennie MJ, Marcus R, Hintz RL, Hoffman AR. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am J Physiol Endocrinol Metab. 1997;272:E94–9.
53. Friedlander AL, Butterfield GE, Moynihan S, Grillo J, Pollack M, Holloway L, et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab. 2001;86:1496–503.
54. Scicchitano BM, Rizzuto E, Musarò A. Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1. Aging. 2009;1:1451.